ARLINGTON HEIGHTS, IL — The Breast Surgery Collaborative Community (BSCC) has officially initiated a pivotal move to refine the landscape of informed consent in plastic surgery. By submitting a revised proposal for the FDA’s Breast Implant Patient Decision Checklist to the federal public docket, the coalition is seeking to transform a document that has, since its 2022 inception, become a subject of intense debate among surgeons, patients, and regulatory bodies.
The move marks a significant shift in how medical devices are discussed between clinicians and those seeking elective or reconstructive surgery. At its core, the initiative seeks to balance the rigorous safety mandates of the Food and Drug Administration (FDA) with the practical, often overwhelming, realities of a clinical consultation.
The Core Objective: Enhancing Clarity and Shared Decision-Making
Since the FDA mandated the Patient Decision Checklist in 2022, the document has been intended to ensure that every patient—regardless of whether they are undergoing breast augmentation or reconstruction—is fully cognizant of the risks associated with breast implants, including BIA-ALCL (Breast Implant-Associated Anaplastic Large Cell Lymphoma) and systemic symptoms often colloquially referred to as "Breast Implant Illness."
However, the implementation of the original checklist faced immediate friction. Clinicians reported that the document’s length and density often hindered, rather than helped, the flow of communication. Patients, conversely, expressed that the sheer volume of information could lead to "information fatigue," where the most critical safety data became buried in legalistic phrasing.
"The goal is not to reduce the amount of information provided to the patient, but to increase the comprehension of that information," says the BSCC in its proposal summary. By streamlining the language and focusing on a more concise, logical flow, the BSCC aims to foster a more effective shared decision-making process. This approach assumes that an informed patient is a safer patient—provided the information is delivered in a format that encourages, rather than impedes, dialogue.
Chronology of a Regulatory Evolution
The 2022 Mandate
The FDA’s original 2022 requirement was a landmark moment for patient safety, designed to standardize the informed consent process across the United States. It mandated that surgeons discuss a specific checklist with patients, ensuring that risks, device types, and long-term maintenance requirements were explicitly reviewed.
The Feedback Loop
Within months of the mandate, the limitations of the checklist became apparent. Medical societies, including the American Society of Plastic Surgeons (ASPS) and The Aesthetic Society, began gathering anecdotal evidence from members. The recurring theme was a disconnect: surgeons felt like "checkbox administrators" rather than educators, and patients often felt overwhelmed by the technical nature of the document.
The Formation of the BSCC
Recognizing that a top-down mandate required bottom-up refinement, the Breast Surgery Collaborative Community (BSCC) was formed. By bringing together a diverse table of stakeholders—including surgeons, medical device manufacturers, and, crucially, patient advocates from organizations like the Breast Implant Safety Alliance (BISA) and FORCE—the group began a consensus-based drafting process.
The Public Docket Submission
The current submission to the FDA public docket represents the culmination of this collaborative effort. It is not merely a revision; it is a fundamental redesign based on the premise that educational tools should be optimized for the human experience of the clinical consultation.
Supporting Data: Why Change Was Necessary
The impetus for this revision is supported by both qualitative and quantitative feedback. In various surveys conducted by plastic surgery professional organizations, a significant majority of surgeons noted that the current checklist’s length—often running into multiple pages of dense text—led to a "check-the-box" mentality.
The "Information Overload" Phenomenon
Cognitive psychology research in medical settings suggests that when patients are presented with exhaustive legal disclosures during high-anxiety moments (such as pre-surgical consultations), their ability to retain critical safety information drops significantly. The BSCC’s proposal utilizes "plain language" standards, which prioritize readability scores, ensuring that the critical risks are prominent and easily digestible.
The Role of Diverse Stakeholders
The BSCC’s internal review process included:
- Patient Advocates: Ensuring that the language reflects the anxieties and questions real patients bring to the table.
- Surgeons: Providing the clinical perspective on how to integrate the checklist into a standard 30- to 60-minute office visit.
- Manufacturers: Providing regulatory oversight to ensure that the revised document remains compliant with FDA safety warnings and labeling requirements.
Official Responses and Perspectives
The BSCC, as an entity, functions as a "collaborative community" under the FDA framework. This is a deliberate organizational choice, as it provides a formal conduit between the private sector and the regulatory agency.
"We are not looking to bypass safety standards," a spokesperson for the BSCC noted during the submission. "We are looking to make them work. If a patient is too intimidated by the length of a document to actually read it, the goal of informed consent has failed. Our goal is to make this document a centerpiece of the conversation, not a hurdle to it."
Patient advocates involved in the process have lauded the move. By having a seat at the table, advocates were able to insist on the inclusion of specific, patient-centric language that addresses the long-term reality of living with implants, rather than focusing solely on the surgical event itself.
Implications for the Future of Plastic Surgery
The implications of this proposal extend far beyond the specific text of the checklist. If adopted, the revised document could serve as a model for how the FDA manages patient education in other fields of elective and reconstructive surgery.
Impact on Clinical Practice
For plastic surgeons, a successful revision would mean a more efficient, high-quality consultation. By streamlining the document, surgeons can dedicate more time to addressing specific patient history and personalized risk factors rather than navigating a generic, overly broad checklist.
Impact on Patient Safety
Safety in breast surgery is a multi-dimensional issue involving product longevity, surgical technique, and post-operative monitoring. A clearer, more concise checklist helps patients understand that their responsibility for their own health does not end when they leave the operating room. It emphasizes the need for regular imaging and the monitoring of symptoms, which are crucial for long-term health outcomes.
The Regulatory Precedent
The FDA’s willingness to engage with the BSCC’s collaborative model demonstrates an openness to industry-led innovation. Should this proposal be successful, it will likely encourage other medical device sectors to form similar collaborative communities to address regulatory pain points, potentially leading to a more agile and responsive FDA approval and monitoring process.
How to Participate: A Call for Public Comment
The BSCC and the FDA are inviting all interested parties—including patients who have undergone breast implant surgery, surgeons, nurses, and researchers—to review the proposed changes.
The public comment period is open until December 1, 2026. This is a rare opportunity for the public to directly influence the regulatory documents that govern their medical care.
Submission Details:
- Portal: https://www.regulations.gov/comment/FDA-2019-D-4467-1386
- Tracking Number: You must include mt7-xgl2-2crx in your comment to ensure it is correctly associated with the BSCC proposal.
The BSCC emphasizes that constructive feedback—specifically suggestions on how to improve the readability or content of the checklist—will be prioritized. They are specifically looking for comments that address whether the new format makes the risks easier to understand without losing the nuance required for a comprehensive informed consent process.
Conclusion: A Collaborative Path Forward
The effort to revise the FDA’s Breast Implant Patient Decision Checklist is a testament to the power of the "collaborative community" model. By acknowledging that the original document, while well-intentioned, required refinement to be truly effective, the BSCC has taken a significant step toward empowering patients.
As medicine becomes increasingly complex, the documents that define the patient-physician relationship must evolve. They must remain, above all, accessible, transparent, and grounded in the realities of the clinical environment. Whether through the lens of a surgeon managing a busy practice or a patient navigating the life-changing decision to undergo breast surgery, the objective remains the same: a safer, more informed, and more empathetic standard of care.
Through this initiative, the BSCC is not just editing a form; it is refining the culture of informed consent in one of the most common surgical procedures in the world. As the comment period progresses, the medical community will be watching closely, awaiting a final decision that could set a new standard for patient-centered regulatory communication.
Members of the Breast Surgery Collaborative Community (BSCC)
- William P. Adams Jr., MD (The Aesthetic Society/The Aesthetic Foundation)
- Scot B. Glasberg, MD (ASPS/PSF)
- George Chatson, MD (ASPS/PSF)
- Jennifer Cook (Patient and Advocate, BISA)
- Lynn Damitz, MD (ASPS/PSF)
- Melinda Haws, MD (The Aesthetic Society/The Aesthetic Foundation)
- Amanda Hynum (Patient Advocate / Oregon Health and Science University)
- Cynthia Johnson, RN (Patient Advocate)
- Debra Johnson, MD (At Large PS Representative)
- Meristacia Kingston, MD (Patient Advocate, Pediatric Hospitalist Fellow)
- Patricia McGuire, MD (The Aesthetic Society/The Aesthetic Foundation)
- Kimberly Platt, MSN, RN, CAPA (Patient Advocate, Registered Nurse)
- **Sheryl Robinson-Collins*** (Head of Regulatory Affairs, Mentor Worldwide LLC)
- **Margie Rose, MPH*** (Head of Global Regulatory Affairs, Establishment Labs/Motiva)
- **Sara Saul, PhD*** (Head of Medical Affairs, Tiger Aesthetics/Sientra)
- Briana Theroux (At Large Patient / Author / Nutrition Psychology)
- **Jamil Ahmad, MD*** (The Aesthetic Society President)
- **C. Bob Basu, MD, MBA, MPH, FACS*** (ASPS President)
*Non-voting members.
About the Author
